Sign in or create an account to add this stock to your watchlist.
About Tyme Technologies (NASDAQ:TYME)
Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company has a co-development agreement with the University of California San Francisco to evaluate SM-88 therapy in prostate cancer. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TYME
CUSIPN/A
Phone646-205-1603
Debt
Debt-to-Equity RatioN/A
Current Ratio3.40
Quick Ratio3.40
Price-To-Earnings
Trailing P/E Ratio-15.72
Forward P/E Ratio-12.30
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book35.38
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-15,200,000.00
Net MarginsN/A
Return on Equity-219.60%
Return on Assets-152.87%
Miscellaneous
EmployeesN/A
Outstanding Shares99,800,000
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
What price target have analysts set for TYME?
3 Wall Street analysts have issued twelve-month price objectives for Tyme Technologies' stock. Their forecasts range from $7.00 to $9.50. On average, they anticipate Tyme Technologies' share price to reach $8.25 in the next twelve months. View Analyst Ratings for Tyme Technologies.
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include Biohaven Pharmaceutical (BHVN), Epizyme (EPZM), Uniqure (QURE), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), Retrophin (RTRX), Athenex (ATNX), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), Lexicon Pharmaceuticals (LXRX), Mirati Therapeutics (MRTX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Zai Lab (ZLAB) and Endocyte (ECYT).
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, CEO & Director (Age 55)
- Mr. Michael S. Demurjian, Chief Operating Officer and Director (Age 51)
- Mr. Ben R. Taylor, Pres & CFO (Age 41)
- Dr. Jonathan M. Eckard, Chief Scientific Affairs Officer
- Dr. Giuseppe Del Priore M.D., MPH, Chief Medical Officer (Age 56)
Has Tyme Technologies been receiving favorable news coverage?
News coverage about TYME stock has trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tyme Technologies earned a media sentiment score of 0.01 on Accern's scale. They also assigned press coverage about the company an impact score of 44.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Tyme Technologies' major shareholders?
Tyme Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.55%), Farallon Capital Management LLC (1.43%) and Family Management Corp (0.14%). Company insiders that own Tyme Technologies stock include Michael Demurjian and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.
Which institutional investors are buying Tyme Technologies stock?
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $2.83.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $306.89 million. The company earns $-15,200,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 44 WALL STREET 12TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-205-1603 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tyme Technologies (NASDAQ:TYME) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Tyme Technologies in the last 12 months. Their average twelve-month price target is $8.25, suggesting that the stock has a possible upside of 191.52%. The high price target for TYME is $9.50 and the low price target for TYME is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.25 | $8.25 | $8.25 | $7.00 |
| Price Target Upside: | 191.52% upside | 94.58% upside | 94.58% upside | 88.17% upside |
Tyme Technologies (NASDAQ:TYME) Consensus Price Target History
Tyme Technologies (NASDAQ:TYME) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Tyme Technologies (NASDAQ:TYME) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tyme Technologies (NASDAQ TYME) News Headlines
| Source: |
|
Tyme Technologies (NASDAQ:TYME) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tyme Technologies (NASDAQ:TYME) Income Statement, Balance Sheet and Cash Flow Statement
Tyme Technologies (NASDAQ TYME) Stock Chart for Monday, May, 21, 2018
Loading chart…
